Hassman Research Institute, LLC
175 Cross Keys Road, Berlin, NJ 08009 MAP
Located on a large campus in Berlin, New Jersey, just twenty minutes from Philadelphia, Hassman Research Institute (HRI) is a leading clinical research organization with over 35 years of experience conducting Phase I-IV clinical trials in a wide variety of therapeutic areas, including addictions, general medicine, hepatic and renal, Human Abuse Liability (HAL), medical/infectious disease, neurology, pain, psychiatry, dermatology, sleep, and ophthalmology.
HRI offers an outstanding team of experts who oversee the setup and conduct of each clinical study. Dr. Howard Hassman, CSO and Principal Investigator, has vast knowledge of clinical research with over 30 years of experience, and is considered an expert in the field of Psychopharmacology. He has an extensive background in psychodynamic psychotherapy, pain management, and addiction medicine. Dr. Larry Ereshefsky, CSO, Early Phase Development, is an internationally recognized thought leader in clinical translational central nervous system research. Under their leadership, HRI is well-positioned to provide the scientific guidance and operational expertise needed to ensure the success of its clinical research.
HRI is affiliated with a large network of multi-specialty practices in the South Jersey and Philadelphia area, which offers unique access to a wide range of specialists and patient populations. In total, there are seven locations offering a total of fourteen PCs and sixteen specialists, allowing HRI the capability to conduct studies in all indications except Oncology and OBGYN. On the HRI campus there are fourteen private practices with physicians that serve as sub-investigators. Their specialties include addictions, cardiology, dermatology, endocrinology, gastroenterology, neurology, pain management, and psychiatry. HRI enrolls their studies with patients that come directly from its family practice database of over 75,000 patients. With access to such a large patient population, HRI has a proven track record of successfully conducting studies in elderly patients, adolescents, pediatrics, adults, healthies, disease state, and special populations.
Download the HRI fact sheet.
Download a presentation about HRI’s general capabilities.
Early Phase Unit
With the newly expanded Early Phase Unit, HRI can house up to 40 subjects in private or semi-private rooms. The secure inpatient unit has two separate wings, providing the controlled environment needed to accommodate separate patient populations as well as translational studies, QTc, ERP/QEEG, pain models, etc. Centrally located in the unit is the onsite Pharmacy with a ventilated laminar flow hood with compounding capabilities, and a CLIA Waived lab. The unit offers safety resources required for the unique needs of Human Abuse Liability (HAL) studies. Additional amenities in the unit are two full time patient liaisons to enhance retention, TVs in every patient room, access to computers for all subjects, board games, video games, and large common areas.
Download the Early Phase Unit fact sheet.
- Research Unit 1: Outpatient CNS & Addiction Building
- Research Unit 2: Early Phase Unit
- Research Unit 3: General Medicine Building
Howard Hassman, DO, CSO, Principal Investigator. Board Certified in Family Practice.
Larry Ereshefsky, PharmD, CSO, Early Phase Development. Internationally recognized thought leader in clinical translational central nervous system research.
Michael Hassman, DO, Medical Director, Principal Investigator. Board Certified in Family Practice.
Roberta Ball, DO, Principal Investigator. Board Certified in Psychiatry.
Elan Cohen, PhD, Principal Investigator. Licensed Clinical Psychologist.
Larry Shusterman, DO, Medical Director of Inpatient Services, Principal Investigator. Board Eligible Internal Medicine.
Elissa Hassman, DO, Principal Investigator, Sub-Investigator. Board Certified in Ophthalmology.
Erica S. Perilstein, MD, Sub-Investigator. Board Certified in Dermatology
Ashok Joseph, MD, Rater, Sub-Investigator.
Mike Alfano, RPh, JD, Pharmacist.